Catalyst Dossier · compiled by CeliA 🧫

Vertex Pharmaceuticals Incorporated (VRTX)

Pharmaceutical Preparations · market cap $114.6B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Vertex Pharmaceuticals (VRTX) is a large-cap specialty pharma with $132.6B market cap, anchored by a deep cystic fibrosis (CF) franchise spanning multiple approved and pipeline CFTR modulator combinations. Beyond CF, Vertex is advancing programs in acute pain (Suzetrigine/VX-548), Type 1 diabetes (VX-880, cell therapy), proteinuric kidney disease (VX-147/Inaxaplin), and gene editing (Casgevy for sickle cell disease), with 2025 revenues of $12.0B and net income of $3.95B.

The catalyst path

2026-08-03Earningsimp 5/10
2026-09-17 (est.)Phase 3 · Biological/Vaccineimp 9/10
2026-10-30 (est.)Phase 3 · VX-121/TEZ/D-IVAimp 9/10
2026-12-23 (est.)Phase 2 · IVAimp 7/10
2026-12-30 (est.)Phase 2 · Inaxaplinimp 7/10
2027-01-25 (est.)Phase 3 · Suzetrigineimp 9/10
2027-01-27 (est.)PDUFA · Povetaciceptimp 8/10
2027-02-02 (est.)Phase 2 · VX-670imp 7/10

Pipeline

Asset	Phase	Indication
VX-548	Phase 2	Acute Pain
Lumacaftor	Phase 3	Cystic Fibrosis
VX-661	Phase 2	Cystic Fibrosis
Cethrin	Phase 2	Spinal Cord Injury
ELX/TEZ/IVA	Phase 3	Cystic Fibrosis
VX-661 plus ivacaftor combination	Phase 3	Cystic Fibrosis
IVA	Phase 3	Cystic Fibrosis
VX-150	Phase 2	Osteoarthritis
Tezacaftor/Ivacaftor	Phase 3	Cystic Fibrosis
LUM/IVA	Phase 3	Cystic Fibrosis
Ivacaftor	Phase 3	Cystic Fibrosis
Ivacaftor 25 mg/75 mg	Phase 2	Cystic Fibrosis
VX-702	Phase 2	Rheumatoid Arthritis
VX-445/TEZ/IVA	Phase 3	Cystic Fibrosis
Inaxaplin	Phase 2	Proteinuric Kidney Disease
VX-880	Phase 3	Type 1 Diabetes
VX-121	Phase 2	Cystic Fibrosis
VX-787	Phase 2	Influenza Virus
ribavirin	Phase 3	Hepatitis C
VX-222	Phase 2	Chronic Hepatitis C Virus

Price & technical context

3-month

+11.8%

6-month

+6.0%

12-month

+3.5%

52-wk range

$366.54–$529.59

vs 50-day MA

+9.5%

vs 200-day MA

+11.2%

Realized vol

36.3%

Max drawdown

-29.1%

Daily closes through 2026-07-09. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VRTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.